Evidence map›Paper›PMID 23728799›Full record

ArticleClinical & experimental metastasis2013

SPRR2A expression in cholangiocarcinoma increases local tumor invasiveness but prevents metastasis.

Susan Specht, Kumiko Isse, Isao Nozaki, John G Lunz, Anthony J Demetris

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & experimental metastasis, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. The 1q21.3 region driver geneTranslational cancer research · 2022
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Increased EphB2 expression predicts cholangiocarcinoma metastasis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Susan SpechtThomas E. Starzl Transplantation Institute, Pittsburgh, PA, 15260, USA.
Kumiko Isse
Isao Nozaki
John G Lunz
Anthony J Demetris
University of Pittsburgh Medical Center · USShikoku Cancer Center · JP

Funding

Interdisciplinary Training in Transplantation BiologyT32AI074490 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Angus W Thomson · 2007 to 2026
$4.2M
INTERLEUKIN 6 AND HUMAN BILIARY EPITHELIAL PROLIFERATIONR01DK049615 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DEMETRIS, ANTHONY J · 1996 to 2006
$1.4M
NIAID NIH HHS T32 AI074490NIDDK NIH HHS DK49615-07
6 · The paper itself

Abstract

Cholangiocarcinoma morbidity and mortality is attributable to local invasiveness and regional lymph node and distant organ metastasis. Cholangiocarcinoma progression follows a series of sequential events that resemble wound healing reactions: local invasion resembles the epithelial migration phase involving epithelial-mesenchymal transition (EMT); colonization at distant sites resembles epithelial restitution seen during the reverse process, mesenchymal-epithelial transition (MET). In this study we compare the in vivo local and metastatic growth potential of cholangiocarcinoma cell lines with respect to expression of a novel pSTAT3-dependent, biliary epithelial cell wound healing protein, small proline-rich protein 2A (SPRR2A). SPRR2A has been associated with local aggressiveness, but decreased metastatic capabilities in other cancers. Stable SPRR2A transfection into two cholangiocarcinoma cell lines (SG231 and HuCCT-1), previously shown by us to induce permanent EMT, resulted in local aggressiveness but an inability to form metastases. In contrast, SPRR2A-negative epithelial control cells showed relatively poor local aggressiveness, but readily formed metastatic tumors. Post-intrasplenic injection cell tracking showed that: (a) mesenchymal (SPRR2A+) cells were not trapped in the liver, but were rapidly cleared through mesenteric lymph nodes and did not form metastases; whereas (b) epithelial (SPRR2A-) controls were primarily entrapped within MUC-1-associated liver "micro-infarcts" that later evolved into metastatic colonies. SPRR2A-associated tumor behavior was mimicked by MUC1 shRNA, which induced EMT and, like SPRR2A+ cells, showed reduced metastatic capabilities. Cholangiocarcinoma local invasion involves EMT processes, whereas MET and MUC1 expression promote metastasis. A better understanding of disease progression should help target treatment for this deadly neoplasm.

Indexed as

AnimalsBile Duct NeoplasmsBile Ducts, IntrahepaticCholangiocarcinomaCornified Envelope Proline-Rich ProteinsDown-RegulationEpithelial-Mesenchymal TransitionFlow CytometryHumansMiceMice, SCIDMucin-1Neoplasm InvasivenessNeoplasm MetastasisPolymerase Chain ReactionCornified Envelope Proline-Rich ProteinsMucin-1SPRR2A protein, human

Identifiers

PMID23728799
OpenAlexW2013512559

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.